Renal Cell Carcinoma
Last Posted: Aug 27, 2020
- Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population.
Suh Jungyo et al. BMC urology 2020 Aug 20(1) 125
- An optimal prognostic model based on gene expression for clear cell renal cell carcinoma.
Xu Dan et al. Oncology letters 2020 Sep 20(3) 2420-2434
- Prognostic Value of DNA Methylation-Driven Genes in Clear Cell Renal Cell Carcinoma: A Study Based on Methylation and Transcriptome Analyses.
Hu Maolin et al. Disease markers 2020 20208817652
- Clinical predictors of a positive test result in patients undergoing genetic evaluation for a hereditary kidney cancer syndrome.
Kokorovic Andrea et al. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2020 Mar
- A 13-gene risk score system and a nomogram survival model for predicting the prognosis of clear cell renal cell carcinoma.
Zhang Chao et al. Urologic oncology 2020 Jan
- miR-142-3p as a novel biomarker for predicting poor prognosis in renal cell carcinoma patients after surgery.
Peng Xiqi et al. The International journal of biological markers 2019 Aug 1724600819866456
- Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series.
Kennedy John M et al. Medical oncology (Northwood, London, England) 2019 Jul 36(9) 74
- Lynch syndrome in urologic malignancies - what does the urologist need to know?
Goldberg Hanan et al. Urology 2019 Jul
- Circulating obesity-driven biomarkers are associated with risk of clear cell renal cell carcinoma: a two-stage, case-control study.
Wang Qinchuan et al. Carcinogenesis 2019 Apr
- Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers.
Park Jee Soo et al. Computational and structural biotechnology journal 2019 17371-377
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
- NIH Information (7)
- COVID-19 (3)
- Human Genome Epidemiologic Studies (448)
- GWAS Studies (7)
- Human Genomics Translation/Implementation Studies (67)
- Genomic Tests Evidence Synthesis (7)
- Genomic Tests Guidelines (2)
- Non-Genomics Precision Health (11)
- Reviews/Commentaries (34)
- Ethical/Legal and Social Issues (ELSI) (1)
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.